Eli Lilly (LLY) plans to invest at least $27 billion to build four new pharmaceutical manufacturing sites in the U.S., as the company looks to ramp up its domestic drug productions amid the threat of possible tariffs.

Eli Lilly, which had committed to $23 billion in domestic investments from 2020-2024, expects the facilities will "create more than 3,000 jobs for highly skilled workers, including engineers, scientists, operations personnel and lab technicians," along with nearly 10,000 construction jobs. Site locations are expected to be announced late this year with the plants coming online within five years. 

The announcement after President Trump reportedly said last week that he planned to impose tariffs of 澳洲幸运5官方开奖结果体彩网:at least 25% on pharmaceutical imports. A few days later, Trump met privately with pharmaceutical CEOs, including Eli Lilly's David Ricks, and urged them to shift manufacturing to the U.S., according to a report from Bloomberg.

Shares of Eli Lilly rose 1% Wednesday afternoon and are up about 18%🅰 since the start of thꦿe year.

Apple Announced Ma🐼ssive Domestic Investmentꦜ Earlier This Week

Apple (AAPL) said on Monday it plans to spend more than 澳洲幸运5官方开奖结果体彩网:$500 billion in the U.S. over the next four years, including on the production of 澳洲幸运5官方开奖结果体彩网:artificial intelligence servers previously made abroad at a new Texas-based factory. Apple said it pl𓆉ans to hire around 20,000 people for the Houston facility, which it expects will open in 2026. 

Meanwhile, Intel (INTC) has been at the subject of speculation that Taiwan Semiconductor Manufacturing Co. (TSM) 澳洲幸运5官方开奖结果体彩网:could buy its struggling foundry business, creating a new U.S.-based chipmaking entity with support from the world's largest semiconductor manufacturer. Those discussions come as Vice President 澳洲幸运5官方开奖结果体彩网:JD Vance said the Trump administration wants AI chips to be designed and manufactured domestically.